Skip to main content
. Author manuscript; available in PMC: 2022 May 3.
Published in final edited form as: J Med Chem. 2020 Oct 6;63(20):11934–11944. doi: 10.1021/acs.jmedchem.0c01198

Figure 5.

Figure 5.

In vivo efficacy of HSGN-218 against CDI recurrence. Mice were treated with HSGN-218 (50 mg/kg), vancomycin (10 mg/kg) or the vehicle for 5 days and treatments were stopped thereafter. Kaplan–Meier survival curves were analyzed using a log-rank (Mantel–Cox) test. Asterisks (*) denote statistically significant difference between mice treated with either HSGN-218, or vancomycin in comparison with the vehicle-treated mice. Pound (#) denotes statistically significant difference between mice treated with compound HSGN-218 in comparison with vancomycin-treated mice